Loading
A phase 3 trial of Sotorasib, Panitumumab in colorectal cancer, run by Amgen, now recruiting.
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation is a phase 3 interventional study registered as NCT06252649 by Amgen, with 450 participants planned, started 2024-07-17 and due to reach its primary completion in 2028-09-25. Interventions recorded: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Panitumumab, Sotorasib, Amgen, KRAS & RAS inhibitors.
Shares CodeBreaK 300, KRAS G12C-mutant colorectal cancer, Monoclonal antibodies, Colorectal cancer.
Shares CodeBreaK 300, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
Shares CodeBreaK 300, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
Shares CodeBreaK 300, Panitumumab, Sotorasib, KRAS G12C-mutant colorectal cancer.
Shares KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors, Monoclonal antibodies, Colorectal cancer.
Shares Sotorasib, Amgen, KRAS & RAS inhibitors.
Shares Panitumumab, Amgen, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/